| 172.5485 0.099 (0.06%) | 09-16 10:09 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 211.27 | 1-year : | 246.77 |
| Resists | First : | 180.88 | Second : | 211.27 |
| Pivot price | 166.16 |
|||
| Supports | First : | 165.94 | Second : | 156.7 |
| MAs | MA(5) : | 170.24 |
MA(20) : | 167.69 |
| MA(100) : | 151.53 |
MA(250) : | 152.8  |
|
| MACD | MACD : | 0.9 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.2 |
D(3) : | 67.3 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 203.91 | Low : | 66.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ICLR ] has closed below upper band by 4.7%. Bollinger Bands are 26.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 173.14 - 173.82 | 173.82 - 174.42 |
| Low: | 165.83 - 166.67 | 166.67 - 167.4 |
| Close: | 170.98 - 172.37 | 172.37 - 173.57 |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Sat, 12 Sep 2026
ICON plc Stock Price: ICLR Stock Chart, Market Cap & News Today - CoinGecko
Fri, 28 Aug 2026
How ICON’s Mixed Q1 Earnings and Reaffirmed 2026 Outlook Could Impact ICON (ICLR) Investors - Sahm
Tue, 28 Jul 2026
ICON plc rises after Anthropic deal, IQVIA earnings (ICLR:NASDAQ) - Seeking Alpha
Tue, 23 Jun 2026
ICON Public Limited Company ($ICLR) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Tue, 02 Jun 2026
Is ICON Stock Finally Priced for Recovery After a $3.9B Backlog Cut and a Q4 2025 EPS Miss? - TIKR.com
Mon, 01 Jun 2026
McIntyre Partnerships Sold Its Position in ICON Public Limited Company (ICLR). Here’s Why - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 77 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 108.2 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 2,600 (K) |
| EPS | 0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 121.55 |
| Profit Margin | 0.3 % |
| Operating Margin | 9.4 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | 0.2 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 25.66 |
| Sales Per Share | 107.45 |
| EBITDA (p.s.) | 6.78 |
| Qtrly Earnings Growth | -63.3 % |
| Operating Cash Flow | 1,110 (M) |
| Levered Free Cash Flow | 623 (M) |
| PE Ratio | 273.22 |
| PEG Ratio | 0.5 |
| Price to Book value | 1.43 |
| Price to Sales | 1.62 |
| Price to Cash Flow | 12.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|